Biocon Anticipates Stronger H2 FY25 Growth Driven by New Product Launches and Volume Expansion

Pharma giant Biocon Ltd reported a net loss of ₹16 crore in its quarterly earnings for the period ending September 30, falling short of market and analyst expectations. Despite the setback, the company is optimistic about an improved performance in the second half of FY25.

In an interview with BusinessLine, Biocon's CEO and Managing Director, Siddharth Mittal, outlined the company’s strategic alignment and reiterated its commitment to achieving this year’s growth objectives. Mittal emphasized that upcoming product launches and higher production volumes are expected to drive Biocon’s growth trajectory in the latter half of the fiscal year.

HBL